Please login to the form below

Not currently logged in
Email:
Password:

Verona appoints chief financial officer

Richard Bungay brings experience from Chroma, Celltech and AstraZeneca

Verona Pharma Richard BungayVerona has named Richard Bungay as the company's chief financial officer to replace Danny Lowe.

Bungay joins the UK-based biotech initially on a part-time basis as it looks to develop its portfolio of investigational medicines for respiratory diseases.

His most recent position was as part-time CEO of fellow UK biotech Chroma Therapeutics, which focuses on the development of novel small molecules for inflammation and oncology, having previously served as the company's chief financial officer.

Prior to his time at Chroma, Bungay was director of corporate communications and strategic planning at Celltech and spent several years as finance director within the respiratory and inflammation therapy area at AstraZeneca.

Dr Jan-Anders Karlsson, CEO of Verona Pharma, said: "Richard's experience in financial management of innovative R&D-based businesses as well as his experience in investor relations will be invaluable to Verona Pharma as we move our key clinical programmes forward and grow the company.”

10th September 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics